1773. HIV Testing in a Cancer Center
Session: Poster Abstract Session: Viral Infections; Pathogenesis and Epidemiology
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • Granwehr IDWeek 2013 1773.pdf (627.1 kB)
  • Background: Since 2006, routine HIV testing has been recommended by the Centers for Disease Control and Prevention (CDC) for those between 13 and 64 years of age.  HIV is associated with various cancers, including classically AIDS-related cancers (e.g. Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and cervical cancer) and non-AIDS-associated malignancies (e.g., lung, liver, anal). HIV testing practices in cancer patients have not been well characterized. We describe the screening pattern and the impact of CDC recommendations on HIV testing at a major cancer center.   

    Methods: Retrospective data was obtained on HIV testing performed between 2000 and 2011 from a laboratory database.  Testing of all patients presenting to a major cancer center for evaluation and those who underwent treatment with radiation, surgery, and/or chemotherapy is described. Chi-square statistic was used to compare patients tested before and after 2006, when the CDC recommended routine HIV testing for cancer patients. 

    Results: HIV testing among all patients evaluated at the cancer center ranged from 24.2% in 2000 to 19.9% in 2006 to 21.5% in 2011.  HIV testing among those receiving cancer treatment (e.g., radiation, chemotherapy, and/or surgery), ranged from 48.9% in 2000 to 35.8% in 2006 to 40.6% in 2011.  Patients evaluated or treated at our center were significantly (p<0.001) more likely to be tested in 2011 compared to 2006.  Of note, however,  the peak HIV testing was in 2000 compared to other years (48.9% 2000 vs. 40.6% 2011, p<0.0001).  In comparison, for the US population over 18 years of age, HIV testing ranged from 32.1% in 2000 to 35.8% in 2006 to 35.9% in 2011.

    Conclusion: Despite CDC recommendations since 2006 to conduct routine HIV screening  and the significant association between HIV and various malignancies, HIV testing is not consistenly performed at a major cancer center.  The impact of the US Preventive Services Task Force issued in April 2013 joining CDC in recommending routine testing for those between 15 and 65 years of age remains to be determined.  In addition, endorsement of the American Society of Clinical Oncology regarding routine HIV testing may be helpful. Other barriers to testing in this population require further exploration.

    Bruno P. Granwehr, MD, M.S., Department of Infectious Diseases, Infection Control and Employee Health. The University of Texas M. D. Anderson Cancer Center, Houston, TX, Kelly Merriman, Ph.D., Emergency Department, UT MD Anderson Cancer Center, Houston, TX, Richard Grimes, Ph.D., Internal Medicine, UT Health Science Center Houston, Houston, TX, Harrys A. Torres, MD, Infectious Department, University of Texas/MD Anderson Cancer Center, Houston, TX, Victor E. Mulanovich, MD, Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, Mark Routbort, MD, PhD., Pathology, UT MD Anderson Cancer Center, Houston, TX and Elizabeth Chiao, MD, Baylor College of Medicine, Houston, TX

    Disclosures:

    B. P. Granwehr, None

    K. Merriman, None

    R. Grimes, None

    H. A. Torres, Merck&Co., Inc.: Consultant, Research grant
    Novartis: Consultant, None
    Astellas: Consultant, None
    Pfizer: Consultant, None
    Genentech: Consultant, None
    Vertex Pharmaceuticals: Consultant, Research grant
    Merck&Co.: Grant Investigator, Research grant
    Vertex Pharmaceuticals: Grant Investigator, Research grant

    V. E. Mulanovich, None

    M. Routbort, None

    E. Chiao, None

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.